ArticleOncogene2001
Chromosomal translocation master genes, mouse models and experimental therapeutics.
Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- Prognostic Significance of the Lymphoblastic Leukemia-Derived Sequence 1 (LYL1) GeneExpression in Egyptian Patients with AcuteMyeloid Leukemia.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2014Article
- Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.Scientific reports · 2014Article
- Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies.BMC medical genomics · 2010Article
- Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins.PLoS computational biology · 2009Article
- Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice.Genes, chromosomes & cancer · 2009Article
- The role of CALM-AF10 gene fusion in acute leukemia.Leukemia · 2008Review
- Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice.Cancer research · 2007Article
- Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications.The Journal of clinical investigation · 2007Review
- MicroRNAs and chromosomal abnormalities in cancer cells.Oncogene · 2006Review
- Review
- Causes of oncogenic chromosomal translocation.Trends in genetics : TIG · 2006Review
- CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes.Leukemia · 2005Article
- Molecular pathogenesis of MLL-associated leukemias.International journal of hematology · 2005Review
- Collaborative competition mechanism for gene activation in vivo.Molecular and cellular biology · 2003Article
- Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.Oncogene · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular biologists have elucidated general principles about chromosomal translocations by cloning oncogenes or fusion genes at chromosomal translocation junctions. These genes invariably encode intracellular proteins and in acute cancers, often involve transcription and developmental regulators, which are master regulators of cell fate (e.g. LMO2 which is involved in acute leukaemia). Chromosomal translocations are usually associated with specific cell types. The reason for this close association is under investigation using mouse models. We are trying to emulate the cell-specific consequences of chromosomal translocations in mice using homologous recombination in embryonic stem cells to generate de novo chromosomal translocations or to mimic the consequence of these translocations. In addition, chromosomal translocation genes and their products are important targets for therapy. We have designed new therapeutic strategies which include antigen-specific recruitment of endogenous cellular pathways to affect cellular viability and a novel structured form of antisense to ablate the function of fusion mRNAs. We will evaluate these procedures in the mouse models of chromosomal translocations and the long term aim is to perfect rapid procedures for characterizing patient-specific chromosomal translocations to tailor therapy to individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.